Agenus vs Ginkgo Bioworks
AGEN and DNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and DNA compare
Ginkgo Bioworks is the larger company, worth 2.1 times as much as Agenus ($647M against $309M).
Agenus grew revenue faster over the last twelve months (25.4% versus −13.2% for Ginkgo Bioworks).
Ginkgo Bioworks scores higher on the StockData Score (9 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | DNA |
|---|---|---|
| Size and price | ||
| Market cap | $309M | $647M |
| Share price | $6.87 | $9.61 |
| Change, 1 year | 60.9% | 15.0% |
| Change, 5 years | −90.2% | −98.2% |
| Beta (5Y) | 2.03 | 2.73 |
| Employees | 81 | 485 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 4.9× |
| P/B | – | 1.6× |
| EV/EBITDA | 4.5× | – |
| FCF yield | −33.6% | −26.8% (better) |
| Fair value | – | $9.67 |
| Margin of safety | – | 0.61% |
| Growth | ||
| Revenue growth (TTM) | 25.4% (better) | −13.2% |
| Revenue growth, 5Y average | 5.3% | 17.3% (better) |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | 38.9% (better) | −205% |
| Net margin | – | −192% |
| FCF margin | −77.5% (better) | −133% |
| Return on equity | – | −52.7% |
| Return on invested capital | – | −113% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −1.05 | – |
| Interest coverage | 0.9× | – |
| Current ratio | 0.73 | 4.72 (better) |
| Altman Z-score | −10.71 | −9.15 (better) |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 31.7% | 53.7% |
| Held by insiders | 6.6% | – |
| Insider net buying, 12 months | – | −$5.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 18.1% | – |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- DNA stock overview
- DNA income statement
- DNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.